keyhole limpet hemocyanin + sargramostim

This is a **combination immunotherapy** consisting of **keyhole limpet hemocyanin (KLH)**, a large protein derived from the marine mollusk *Megathura crenulata* used as a highly immunogenic neo-antigen/adjuvant, and **sargramostim**, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). - **KLH** stimulates strong humoral and cellular immune responses, often serving as an immunologic probe or in immunotherapy to enhance adaptive immune responses by activating T and B lymphocytes[6][8]. clinically, KLH has been tested as immunotherapy, especially in bladder cancer, where it acts as a non-specific immunostimulant to promote anti-tumor immunity[2][4]. - **Sargramostim** binds to and activates the granulocyte-macrophage colony-stimulating factor receptor on hematopoietic progenitors, stimulating proliferation and differentiation of granulocytes, macrophages, and dendritic cells, ultimately boosting innate and adaptive immune responses[1][3][9]. It is FDA-approved to accelerate recovery of white blood cells after myelosuppressive therapy. - As a combination, **KLH + sargramostim** is used in research and in some investigational immunotherapy regimens to synergistically enhance antigen-specific and general immune activation, potentially improving cancer immunotherapy and vaccine efficacy. Developers and commercialized products for this specific combination are not established; both KLH and sargramostim are produced independently by various companies.

Other names

KLH + sargramostim